21 analysts have recently assigned a consensus ‘hold’ recommendation to the stock of Moderna (NASDAQ: MRNA). 3 analysts allotted a rating of ‘sell’, 6 assigned ‘hold’, and 7 issued ‘buy’. The company had the average $157.94 price objective for 12 months last year.
On Tuesday, the firm started from $123.47 with the market cap being $49.36 billion. Their lowest in 1 year is $19.31 while the highest is $189.26. Their current, quick, and leverage ratio is 2.43, 2.43, and 0.04. Their 50-day rolling average stands at $157.94 while 200 days is at $108.50.
According to the 25th February report, their quarterly EPS earnings were $0.69 that missed the $0.25 consensus estimate by nearly $0.44. They had a 242.73% net negative margin with a 28.11% negative equity return. Their revenue was $570.80 million that surpassed the $279.41 million estimate.
Market Undertakings Of MRNA Stock
SVB Leerink raised the price objective of MRNA shares to $80 from $69 and gave a rating of ‘underperform’. Chardan Capital lifted it to $182 from $107 and gave a rating of ‘buy’. Morgan Stanley demoted it to $201 from $215 and gave a rating of ‘equal weight’. Barclays upgraded it to $178 from $169 and gave a rating of ‘sell’. Zacks increased it to a rating of ‘hold’ from ‘sell’ and assigned it $166.
Stephane Bancel, the CEO, sold off 11,406 MRNA shares at $159.18 EPS worth $1,758,302.28. Juan Andres, the insider, sold off 5,000 MRNA shares at $112.83 worth $564,150. 29.20% Moderna stock is owned by insiders.
Lindbrook Capital raised its holdings on MRNA stock by almost 81.1%, owning $35,000 worth of shares. Balck Swift purchased a new position and own $26,000 worth of shares. Clearstead Advisors promoted their stake by approximately 733.3%, owning shares priced at $27,000. Institutional investors own 51.21% of Moderna stock.
